- Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
- Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
- Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
- Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
- Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)
- Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
- Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
- Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.39 |
---|---|
High | 1.41 |
Low | 1.32 |
Bid | 1.35 |
Offer | 1.39 |
Previous close | 1.37 |
Average volume | 371.14k |
---|---|
Shares outstanding | 2.53m |
Free float | 2.51m |
P/E (TTM) | -- |
Market cap | 3.47m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼